Polycystic ovary syndrome (PCOS), a condition affecting more than 170 million people worldwide, has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS)
Polycystic ovary syndrome (PCOS), a condition affecting more than 170 million people worldwide, has been officially renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS) following a landmark global consensus study published today in The Lancet.
The new name recognizes that the condition is not a primarily gynecological disorder, but is instead a complex, multisystem condition involving endocrine, metabolic, reproductive, dermatological and psychological health. Additionally, the recategorizing will include updates to clinical guidelines, medical education and international disease classification systems, ensuring the new terminology is adopted consistently worldwide.